Associated Disease Details
| Disease ID: | I12 |
| DO ID: | 10763 |
| Disease Name: | Hypertension |
| Definition: | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 |
| Synonyms: | Hypertensive disease; Hypertensive urgency; hypertension; High blood pressure; HTN; hyperpiesia; vascular hypertensive disorder |
| Class: | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease |
| Related Drugs: | Atorvastatin; Losartan; Moxonidine; Perindopril; Spironolactone; Telmisartan; |
| Mechanism: | Hypertension, a multifactorial disorder resulting from the interplay between genetic predisposition and environmental risk factors, affects ≈30% of adults. Emerging evidence has shown that nonalcoholic fatty liver disease (NAFLD), as an underestimated metabolic abnormality, is strongly associated with an increased risk of incident prehypertension and hypertension. |
| Reference (PMIDs): | 31865799 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D028 | Belapectin | Chemical drug | DB15125 | Gelactin-3 inhibitor; LGALS3 inhibitor | Anti-fibrosis | Failed in clinical trials | Details |
| D033 | Bezafibrate | Chemical drug | DB01393 | PPARA agonist; PPARD agonist; PPARG agonist; NR1I2 partial agonist | Improve insulin resistance; Anti-inflammatory | Under clinical trials | Details |
| D084 | Coenzyme Q10 | Chemical drug | DB09270 | -- | -- | Under clinical trials | Details |
| D209 | Losartan | Chemical drug | DB00678 | AGTR1 antagonist&binder | Anti-fibrosis | Under clinical trials | Details |
| D232 | Moxonidine | Chemical drug | DB09242 | NISCH agonist | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D267 | Perindopril | Chemical drug | DB00790 | ACE inhibitor | Antihypertensive drug | Under clinical trials | Details |
| D271 | Phentermine | Chemical drug | DB00191 | MAOB antagonist; MAOA antagonist; SLC6A2 inhibitor; SLC6A3 inhibitor; SLC6A4 inhibitor; SLC6A2 stimulator; SLC6A3 stimulator | Anorexic; CNS stimulant | Under clinical trials | Details |
| D344 | Spironolactone | Chemical drug | DB00421 | AR antagonist; PGR agonist; NR1I2 | Diuretic drug | Under clinical trials | Details |
| D360 | Telmisartan | Chemical drug | DB00966 | PPARG partial agonist | Improve insulin resistance | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0064 | DB00177 | approved; investigational | small molecule | Valsartan | Therapeutic strategy associated | Details |
| R0065 | DB00178 | approved | small molecule | Ramipril | Therapeutic strategy associated | Details |
| R0072 | DB00195 | approved; investigational | small molecule | Betaxolol | Indication associated | Details |
| R0075 | DB00203 | approved; investigational | small molecule | Sildenafil | Indication associated | Details |
| R0077 | DB00206 | approved; investigational | small molecule | Reserpine | Therapeutic strategy associated | Details |
| R0080 | DB00212 | experimental | small molecule | Remikiren | Indication associated | Details |
| R0084 | DB00217 | approved | small molecule | Bethanidine | Therapeutic strategy associated | Details |
| R0087 | DB00226 | approved | small molecule | Guanadrel | Indication associated | Details |
| R0090 | DB00232 | withdrawn | small molecule | Methyclothiazide | Therapeutic strategy associated | Details |
| R0098 | DB00264 | approved; investigational | small molecule | Metoprolol | Therapeutic strategy associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00005 | 35258483 | Endocr Connect | Menopause-associated risk of cardiovascular disease. | Details |
| A00012 | 35255597 | Endocrinol Metab (Seoul) | The Influence of Obesity and Metabolic Health on Vascular Health. | Details |
| A00013 | 35255263 | Lancet Oncol | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. | Details |
| A00021 | 35251583 | J Healthc Eng | Preliminary Study on Risk Factors for Morbidity of Nonalcoholic Fatty Liver Disease in High-Income Male Population. | Details |
| A00024 | 35251356 | EFSA J | Tolerable upper intake level for dietary sugars. | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | Details |
| A00080 | 35227957 | Clin Res Hepatol Gastroenterol | The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience. | Details |
| A00118 | 35215504 | Nutrients | Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. | Details |
| A00144 | 35209867 | BMC Gastroenterol | Helicobacter pylori infection is not an independent risk factor of non-alcoholic fatty liver disease in China. | Details |
| A00157 | 35204710 | Biomolecules | Posttranscriptional Regulation of Insulin Resistance: Implications for Metabolic Diseases. | Details |
| A00158 | 35204522 | Diagnostics (Basel) | A Comparative Study of the Triglycerides/HDL Ratio and Pseudocholinesterase Levels in Patients with Bladder Cancer. | Details |
| A00168 | 35203457 | Biomedicines | Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. | Details |
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | Details |
| A00197 | 35190357 | Anatol J Cardiol | Fragmented QRS in inferior leads is associated with non-alcholic fatty liver disease, body-mass index, and interventricular septum thickness in young men. | Details |
| A00224 | 35178085 | Gastroenterol Res Pract | The Risk Factors of Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients Undergoing Bariatric Surgery in Iran. | Details |
| A00274 | 35157960 | J Hepatol | Hepatic lymphatic vascular system in health and disease. | Details |
| A00285 | 35152669 | Zhonghua Gan Zang Bing Za Zhi | [Study on the relationship between nonalcoholic fatty liver disease and hepatocellular carcinoma in patients with prior hepatitis B virus infection]. | Details |
| A00286 | 35152526 | Liver Int | Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. | Details |
| A00317 | 35140487 | Diabetes Metab Syndr Obes | The Association Between Vitamin D and Type 2 Diabetes Mellitus Complicated with Non-Alcoholic Fatty Liver Disease: An Observational Cross-Sectional Study. | Details |
| A00320 | 35138548 | Intern Emerg Med | NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. | Details |